Table 1.

Clinicopathologic features of patients with advanced MET exon 14-altered lung cancers.

Patients Treated with MET TKI (N = 75)
Age, median (range)		73 years (44-91 years)
Sex, % (N)	Female	52% (39)
Cigarette smoking, % (N)	Never Former or Current	44% (33) 56% (42)
Histology, % (N)	Adenocarcinoma Sarcomatoid Other	79% (59) 9% (7) 12% (9)
Number of MET TKIs, % (N)	1 2 or more	75% (56) 25% (19)
First MET TKI received, % (N)	Crizotinib Cabozantinib Tepotinib	88% (66) 1% (1) 11% (8)
DNA-based NGS, % (N)	MSK-IMPACT Foundation One	95% (71) 5% (4)
MET Splice Site Region#, % (N)	Intron 13 Acceptor Intron 14 Donor Fusion Other Not Detected by DNA-based NGS	33% (25) 60% (45) 3% (2) 3% (2) 1% (1)
MET Mutation Type#, % (N)	Base substitution Insertion/deletion Large deletion (>35 bp) Fusion Other Note Detected by DNA-based NGS	48% (36) 35% (26) 8% (6) 3% (2) 3% (2) 4% (3)

Percentages in select demographic groups do not add up to 100% due to rounding.